Daily non-political popular news in brief.

St. Jude researchers identify key genetic trigger of acute myeloid leukemia

A gene called N-Myc leads a double life in certain white blood cells, helping to trigger a cancer called acute myeloid leukemia (AML) under some conditions while triggering apoptosis, or cell suicide, under other conditions, according to results of a mouse study done by investigators at St. Jude Children's Research Hospital.

Read more »

Keywords: jude, researchers, identify, key, genetic, trigger, acute, myeloid, leukemia, researcher

« Previous | Next »

Similar news on "St. Jude researchers identify key genetic trigger of acute myeloid leukemia":

1. Kidney cancer drug attacks a major type of acute myeloid leukemia
   01-29-2008 · EurekAlert!
   A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia, the most common and lethal form of adult leukemia, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan. 29 edition of the Journal of the National Cancer Institute.
   Similar news · Read more »
   
2. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
   12-10-2007 · EurekAlert!
   Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days.
   Similar news · Read more »
   
3. Aggressive therapy best for certain AML patients
   08-01-2007 · EurekAlert!
   A new study suggests that acute leukemia patients whose cancer cells show a genetic change that usually predicts a swift return of the disease following remission may remain disease-free longer when given aggressive therapy. The findings apply to people with acute myeloid leukemia whose cancer cells have normal-looking chromosomes and a gene mutation called MLL-PTD.
   Similar news · Read more »
   
4. Molecules might identify high-risk acute-leukemia patients
   01-15-2008 · EurekAlert!
   New research suggests that certain microRNAs might help doctors identify adult acute-leukemia patients who are likely to respond poorly to therapy. The findings showed that both the leukemia cells and their normal counterparts had similar kinds of microRNA, but that the two groups differed in the levels of miRNAs present. The study should improve the understanding of acute myeloid leukemia and could lead to new therapies for patients with few treatment options.
   Similar news · Read more »
   
5. Researchers identify cells that make relapse inevitable in acute lymphoblastic leukemia
   11-09-2006 · EurekAlert!
   Scientists in Australia have discovered that in acute lymphoblastic leukemia (ALL) there are "good" and "evil" clones of the same type of ALL cell. The "evil" cells are clones that have a pre-existing resistance to drugs used for treating ALL, and their presence in a patient means that person will inevitably relapse after chemotherapy, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
   Similar news · Read more »
   
6. CDX2 -- A protein that promotes leukemia
   03-07-2007 · EurekAlert!
   Researchers from Harvard Medical School, Boston, have found that most individuals with acute myeloid leukemia (AML) inappropriately express a protein known as CDX2 in their leukemic cells and that CDX2 has a causal role in the pathogenesis of AML. CDX2 regulates the expression of a number of genes that encode members of the HOX family of proteins, which might provide a new set of targets for the treatment of individuals with AML.
   Similar news · Read more »
   
7. New weapon to fight leukemia
   08-23-2007 · EurekAlert!
   A new study indicates that the drug FTY720 prevents disease in a mouse model of two leukemias -- blast crisis chronic myeloid leukemia and acute lymphocytic leukemia -- caused by the cancer protein BCR-ABL. As the drug also induced cell lines from humans with these leukemias to die in vitro the authors suggest that FTY720 should be considered by researchers and clinicians developing new approaches to treat CML-BC and ALL.
   Similar news · Read more »
   
8. Role for proteomics in identifying hematologic malignancies
   01-11-2007 · EurekAlert!
   Scientists have identified a set of biomarkers that could help clinicians identify a group of hematologic malignancies known as myelodysplastic syndromes (MDS), which affect approximately 300,000 individuals worldwide and often progress to acute myeloid leukemia.
   Similar news · Read more »
   
9. Novel MS drug shows promise in 2 lethal leukemias
   08-28-2007 · EurekAlert!
   A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia. The laboratory and animal study focused on the drug, called fingolimod. Researchers said it might help patients with advanced chronic myelogenous leukemia or acute lymphocytic leukemia, and whose cancer cells show a particular genetic change called the Philadelphia chromosome.
   Similar news · Read more »
   
10. Gene's activity points to more lethal subtype of AML
    07-09-2007 · EurekAlert!
    A new study shows that the activity of a particular gene can identify people who have a more lethal form of acute myeloid leukemia, singling out those patients who should receive more intense therapy. The gene, called ERG (for ETS-related gene), has also been linked to chronic leukemia and to breast and prostate cancer.
    Similar news · Read more »